COVID-19 is associated with high mortality in patients with haematological malignancies (HM) and rate of seroconversion is unknown. The ITA-HEMA-COV project (NCT04352556) investigated patterns of seroconversion for SARS-CoV-2 IgG in patients with HMs. A total of 237 patients, SARS-CoV-2 PCR-positive with at least one SARS-CoV-2 IgG test performed during their care, entered the analysis. Among these, 62 (26·2%) had myeloid, 121 (51·1%) lymphoid and 54 (22·8%) plasma cell neoplasms. Overall, 69% of patients (164 of 237) had detectable IgG SARS-CoV-2 serum antibodies. Serologically negative patients (31%, 73 of 237) were evenly distributed across patients with myeloid, lymphoid and plasma cell neoplasms. In the multivariable logistic regression, chemoimmunotherapy [odds ratio (OR), 3·42; 95% confidence interval (CI), 1·04–11·21; P = 0·04] was associated with a lower rate of seroconversion. This effect did not decline after 180 days from treatment withdrawal (OR, 0·35; 95% CI: 0·11–1·13; P = 0·08). This study demonstrates a low rate of seroconversion in HM patients and indicates that treatment-mediated immune dysfunction is the main driver. As a consequence, we expect a low rate of seroconversion after vaccination and thus we suggest testing the efficacy of seroconversion in HM patients.

COVID-19 elicits an impaired antibody response against SARS-CoV-2 in patients with haematological malignancies / Passamonti, F.; Romano, A.; Salvini, M.; Merli, F.; Porta, M. G. D.; Bruna, R.; Coviello, E.; Romano, I.; Cairoli, R.; Lemoli, R.; Farina, F.; Venditti, A.; Busca, A.; Ladetto, M.; Massaia, M.; Pinto, A.; Arcaini, L.; Tafuri, A.; Marchesi, F.; Fracchiolla, N.; Bocchia, M.; Armiento, D.; Candoni, A.; Krampera, M.; Luppi, M.; Cardinali, V.; Galimberti, S.; Cattaneo, C.; La Barbera, E. O.; Mina, R.; Lanza, F.; Visani, G.; Musto, P.; Petrucci, L.; Zaja, F.; Grossi, P. A.; Bertu, L.; Pagano, L.; Corradini, P.; Derenzini, E.; Marchetti, M.; Scattolin, A. M.; Corso, A.; Tosi, P.; Gherlinzoni, F.; Passerini, C. G.; Cavo, M.; Fava, C.; Turrini, M.; Visco, C.; Zappasodi, P.; Merli, M.; Mora, B.; Vannucchi, A. M.. - In: BRITISH JOURNAL OF HAEMATOLOGY. - ISSN 0007-1048. - 195:3(2021), pp. 371-377. [10.1111/bjh.17704]

COVID-19 elicits an impaired antibody response against SARS-CoV-2 in patients with haematological malignancies

Coviello E.;Romano I.;Lemoli R.;Busca A.;Pinto A.;Candoni A.;Luppi M.;Galimberti S.;Cattaneo C.;Corradini P.;Merli M.;
2021-01-01

Abstract

COVID-19 is associated with high mortality in patients with haematological malignancies (HM) and rate of seroconversion is unknown. The ITA-HEMA-COV project (NCT04352556) investigated patterns of seroconversion for SARS-CoV-2 IgG in patients with HMs. A total of 237 patients, SARS-CoV-2 PCR-positive with at least one SARS-CoV-2 IgG test performed during their care, entered the analysis. Among these, 62 (26·2%) had myeloid, 121 (51·1%) lymphoid and 54 (22·8%) plasma cell neoplasms. Overall, 69% of patients (164 of 237) had detectable IgG SARS-CoV-2 serum antibodies. Serologically negative patients (31%, 73 of 237) were evenly distributed across patients with myeloid, lymphoid and plasma cell neoplasms. In the multivariable logistic regression, chemoimmunotherapy [odds ratio (OR), 3·42; 95% confidence interval (CI), 1·04–11·21; P = 0·04] was associated with a lower rate of seroconversion. This effect did not decline after 180 days from treatment withdrawal (OR, 0·35; 95% CI: 0·11–1·13; P = 0·08). This study demonstrates a low rate of seroconversion in HM patients and indicates that treatment-mediated immune dysfunction is the main driver. As a consequence, we expect a low rate of seroconversion after vaccination and thus we suggest testing the efficacy of seroconversion in HM patients.
195
3
371
377
COVID-19 elicits an impaired antibody response against SARS-CoV-2 in patients with haematological malignancies / Passamonti, F.; Romano, A.; Salvini, M.; Merli, F.; Porta, M. G. D.; Bruna, R.; Coviello, E.; Romano, I.; Cairoli, R.; Lemoli, R.; Farina, F.; Venditti, A.; Busca, A.; Ladetto, M.; Massaia, M.; Pinto, A.; Arcaini, L.; Tafuri, A.; Marchesi, F.; Fracchiolla, N.; Bocchia, M.; Armiento, D.; Candoni, A.; Krampera, M.; Luppi, M.; Cardinali, V.; Galimberti, S.; Cattaneo, C.; La Barbera, E. O.; Mina, R.; Lanza, F.; Visani, G.; Musto, P.; Petrucci, L.; Zaja, F.; Grossi, P. A.; Bertu, L.; Pagano, L.; Corradini, P.; Derenzini, E.; Marchetti, M.; Scattolin, A. M.; Corso, A.; Tosi, P.; Gherlinzoni, F.; Passerini, C. G.; Cavo, M.; Fava, C.; Turrini, M.; Visco, C.; Zappasodi, P.; Merli, M.; Mora, B.; Vannucchi, A. M.. - In: BRITISH JOURNAL OF HAEMATOLOGY. - ISSN 0007-1048. - 195:3(2021), pp. 371-377. [10.1111/bjh.17704]
Passamonti, F.; Romano, A.; Salvini, M.; Merli, F.; Porta, M. G. D.; Bruna, R.; Coviello, E.; Romano, I.; Cairoli, R.; Lemoli, R.; Farina, F.; Venditti, A.; Busca, A.; Ladetto, M.; Massaia, M.; Pinto, A.; Arcaini, L.; Tafuri, A.; Marchesi, F.; Fracchiolla, N.; Bocchia, M.; Armiento, D.; Candoni, A.; Krampera, M.; Luppi, M.; Cardinali, V.; Galimberti, S.; Cattaneo, C.; La Barbera, E. O.; Mina, R.; Lanza, F.; Visani, G.; Musto, P.; Petrucci, L.; Zaja, F.; Grossi, P. A.; Bertu, L.; Pagano, L.; Corradini, P.; Derenzini, E.; Marchetti, M.; Scattolin, A. M.; Corso, A.; Tosi, P.; Gherlinzoni, F.; Passerini, C. G.; Cavo, M.; Fava, C.; Turrini, M.; Visco, C.; Zappasodi, P.; Merli, M.; Mora, B.; Vannucchi, A. M.
File in questo prodotto:
File Dimensione Formato  
Br J Haematol - 2021 - Passamonti - COVID‐19 elicits an impaired antibody response against SARS‐CoV‐2 in patients with.pdf

Open access

Tipologia: Versione pubblicata dall'editore
Dimensione 1.19 MB
Formato Adobe PDF
1.19 MB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1280502
Citazioni
  • ???jsp.display-item.citation.pmc??? 30
  • Scopus 33
  • ???jsp.display-item.citation.isi??? 35
social impact